Last 30 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -34.73 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | 1364.27 | — | 186.92 | 73.21 | 34.63 | 124.42 | 39.70 | 62.41 | 49.11 | 459.35 |
| — | — | — | — | — | — | — | — | — | — | — | +3839.1% | — | +370.8% | +17.3% | -29.5% | -72.9% | -40.7% | -21.7% | -34.5% | +930.1% | |
| P/B Ratio | 24.08 | 15.15 | 12.84 | 9.28 | 5.53 | 3.71 | 3.20 | 3.24 | 4.83 | 3.96 | 3.08 | 2.22 | 3.61 | 3.07 | 2.16 | 3.10 | 2.45 | 2.90 | 3.43 | 3.08 | 3.17 |
| — | +308.4% | +301.2% | +186.6% | +14.6% | -6.3% | +4.0% | +46.1% | +33.8% | +28.9% | +42.6% | -28.5% | +47.3% | +5.8% | -37.2% | +0.5% | -22.7% | -14.7% | -23.2% | -44.2% | -29.1% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | 100.0% | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| — | — | — | — | — | — | — | — | — | — | — | 0.0% | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | -24256.5% | — | -2845.1% | -1071.5% | -402.5% | -2280.5% | -681.1% | -764.7% | -559.3% | -4828.6% |
| — | — | — | — | — | — | — | — | — | — | — | -5926.1% | — | -317.7% | -40.1% | +28.0% | +52.8% | -33.0% | -107.2% | -43.6% | -2119.0% | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | -21770.5% | — | -2570.6% | -970.9% | -368.6% | -2185.0% | -671.6% | -760.7% | -556.8% | -4808.4% |
| — | — | — | — | — | — | — | — | — | — | — | -5806.2% | — | -282.8% | -27.6% | +33.8% | +54.6% | -31.9% | -107.3% | -42.5% | -2136.5% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -58.1% | -31.4% | -29.0% | -22.6% | -17.6% | -12.6% | -9.8% | -10.2% | -9.8% | -8.0% | -6.5% | -12.1% | -12.3% | -10.4% | -8.3% | -8.3% | -12.4% | -11.7% | -10.0% | -8.5% | -8.0% |
| — | -149.8% | -195.0% | -122.6% | -79.7% | -57.7% | -50.4% | +16.3% | +20.0% | +23.7% | +21.5% | -46.7% | +1.3% | +10.5% | +16.8% | +2.6% | -55.3% | -85.3% | -60.9% | -21.6% | -27.2% | |
| ROA | -46.1% | -19.6% | -19.7% | -15.8% | -13.0% | -10.3% | -8.7% | -9.0% | -8.8% | -7.2% | -5.8% | -10.6% | -10.5% | -9.2% | -7.2% | -6.9% | -10.1% | -9.3% | -8.1% | -7.2% | -7.0% |
| — | -89.6% | -127.2% | -75.9% | -49.0% | -44.2% | -48.3% | +15.1% | +16.9% | +21.7% | +19.1% | -53.7% | -4.8% | +1.6% | +11.0% | +3.5% | -43.3% | -66.6% | -50.5% | -21.5% | -35.2% | |
| ROIC | -54.3% | -19.3% | -23.0% | -18.4% | -15.1% | -11.4% | -9.7% | -9.8% | -9.1% | -7.9% | -7.7% | -15.3% | -16.0% | -13.6% | -9.6% | -8.0% | -11.2% | -9.5% | -8.0% | -7.2% | -7.5% |
| — | -68.8% | -138.1% | -87.9% | -65.0% | -43.7% | -25.5% | +36.1% | +42.8% | +41.4% | +19.6% | -91.5% | -42.9% | -42.4% | -19.0% | -11.2% | -49.2% | -31.9% | -15.7% | -23.6% | -53.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.25 | 0.29 | 0.10 | 0.10 | 0.07 | 0.06 | 0.06 | 0.06 | 0.05 | 0.05 | 0.05 | 0.08 | 0.07 | 0.07 | 0.09 | 0.10 | 0.13 | 0.12 | 0.11 | 0.05 |
| — | +246.0% | +351.0% | +62.2% | +79.3% | +31.8% | +26.7% | +24.5% | -26.2% | -20.5% | -23.6% | -48.6% | -21.6% | -47.8% | -44.2% | -15.3% | +92.1% | +174.5% | +170.2% | +60.7% | -24.6% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 7.14 | 11.38 | 6.80 | 7.14 | 8.05 | 11.79 | 13.46 | 14.20 | 14.24 | 15.42 | 18.45 | 13.06 | 9.64 | 11.81 | 16.89 | 10.65 | 9.21 | 7.60 | 9.30 | 9.77 | 12.02 |
| — | -3.5% | -49.5% | -49.7% | -43.5% | -23.5% | -27.1% | +8.7% | +47.8% | +30.6% | +9.2% | +22.7% | +4.6% | +55.4% | +81.6% | +9.0% | -23.3% | -47.3% | -41.6% | +1.5% | +5.5% | |
| Quick Ratio | 7.14 | 11.38 | 6.80 | 7.14 | 8.05 | 11.79 | 13.46 | 14.20 | 14.24 | 15.42 | 18.45 | 13.06 | 9.64 | 11.81 | 16.89 | 10.65 | 9.21 | 7.60 | 9.30 | 9.77 | 12.02 |
| — | -3.5% | -49.5% | -49.7% | -43.5% | -23.5% | -27.1% | +8.7% | +47.8% | +30.6% | +9.2% | +22.7% | +4.6% | +55.4% | +81.6% | +9.0% | -23.3% | -47.3% | -41.6% | +1.5% | +5.5% | |
| Interest Coverage | -45.69 | -26.10 | -36.21 | -29.57 | -25.71 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 30 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RVMD stock.
Revolution Medicines, Inc.'s current P/E is -34.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Revolution Medicines, Inc.'s business trajectory between earnings reports.